Bolt Biotherapeutics Stock Forum

$Bolt Biotherapeutics (BOLT.US)$
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstr...

$Bolt Biotherapeutics (BOLT.US)$ MT Newswires· 2 mins ago
Bolt Biotherapeutics (BOLT) shares were nearly 32% lower in premarket activity Wednesday following the company's announcement late Tuesday that it will stop the development of trastuzumab imbotolimod, BDC-1001, and has trimmed its workforce by about 50%.
The company said the BDC-1001 program is not expected to meet its pre-defined success criteria and it will now focus on developing its other cancer pipeline, which includes a first-in...

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® 2 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 25.86 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $2.53 million which beat the analyst consensus estimate of $1.72 million by 46.98 percent. This is a 19.70 percent increase over sales of $2.11 million the same perio...

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

$Bolt Biotherapeutics (BOLT.US)$ Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

$Bolt Biotherapeutics (BOLT.US)$
It has healthy balance sheet (25% debt) and income, believe it's under value with $1 now...

Upgrades
• $Credicorp (BAP.US)$ : Citigroup Upgrades to Buy from Neutral - PT $161 (from $128)
• $Bank of New York Mellon (BK.US)$ : Citigroup Upgrades to Buy from Neutral
• $CommScope (COMM.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $17 (from $11)
• $Domino's Pizza (DPZ.US)$ : UBS Upgrades to Buy from Neutral - PT $385 (from $430)
• $Gilead Sciences (GILD.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $80 (fr...

Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...

$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
ATLANTA, Mar. 2, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference.
https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-hc-wainwright--co-global-life-sciences-virtual-conference-301238073.html
https://newsfilter.io/a/94932b8a928e6b7df704caecd241da83
...